Leman Yel

Title(s)Emeritus Faculty, Medicine
SchoolSchool of Medicine
Address1001 Health Sciences Road
Irvine CA 92697-3950
Phone(949) 824-4566
vCardDownload vCard

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Pharmacokinetics, safety, and efficacy of 20% subcutaneous immunoglobulin (Ig20Gly) administered weekly or every 2 weeks in Japanese patients with primary immunodeficiency diseases: a phase 3, open-label study. Immunother Adv. 2024; 4(1):ltae001. Kanegane H, Endo A, Okada S, Ohnishi H, Ishimura M, Nishikomori R, Imai K, Nonoyama S, Muramatsu H, Wada T, Kuga A, Sakamoto K, Russo-Schwarzbaum S, Chu LH, McCoy B, Li Z, Yel L. PMID: 38511087; PMCID: PMC10953624.
      View in: PubMed   Mentions:
    2. Population pharmacokinetics of immunoglobulin G after intravenous, subcutaneous, or hyaluronidase-facilitated subcutaneous administration in immunoglobulin-naive patients with primary immunodeficiencies. Int Immunopharmacol. 2024 Feb 15; 128:111447. Li Z, Follman K, Freshwater E, Engler F, Yel L. PMID: 38185032.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    3. A Phase 1 Open-Label Study to Assess the Tolerability, Safety, and Immunogenicity of Hyaluronidase-Facilitated Subcutaneous Immunoglobulin 20% in Healthy Adults. J Clin Immunol. 2023 Dec 22; 44(1):28. Nagy A, Duff K, Bauer A, Okonneh F, Rondon JC, Yel L, Li Z. PMID: 38129731; PMCID: PMC10739571.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCTClinical Trials
    4. Evaluation of body weight-based dosing, alternative dosing regimens, and treatment interruptions for α1-proteinase inhibitors and implications on biochemical efficacy in patients with α1-antitrypsin deficiency. Pulm Pharmacol Ther. 2023 Dec; 83:102265. Li Z, Gaurav M, Yel L. PMID: 37923165.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    5. Effects of Body Mass and Age on the Pharmacokinetics of Subcutaneous or Hyaluronidase-facilitated Subcutaneous Immunoglobulin G in Primary Immunodeficiency Diseases. J Clin Immunol. 2023 11; 43(8):2127-2135. Li Z, Follman K, Freshwater E, Engler F, Yel L. PMID: 37773562; PMCID: PMC10661727.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    6. Hyaluronidase-facilitated subcutaneous immunoglobulin 10% as maintenance therapy for chronic inflammatory demyelinating polyradiculoneuropathy: The ADVANCE-CIDP 1 randomized controlled trial. J Peripher Nerv Syst. 2023 09; 28(3):436-449. Bril V, Hadden RDM, Brannagan TH, Bar M, Chroni E, Rejdak K, Rivero A, Andersen H, Latov N, Levine T, Pasnoor M, Sacconi S, Souayah N, Anderson-Smits C, Duff K, Greco E, Hasan S, Li Z, Yel L, Ay H. PMID: 37314318.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    7. Corrigendum to "Integrated population pharmacokinetics of immunoglobulin G following intravenous or subcutaneous administration of various immunoglobulin products in patients with primary immunodeficiencies" [Int. Immunopharmacol. 113(Part A) (2022) 109331]. Int Immunopharmacol. 2022 Dec 15; 114:109555. Li Z, Follman K, Freshwater E, Engler F, Yel L. PMID: 36527876.
      View in: PubMed   Mentions:    Fields:    
    8. Integrated population pharmacokinetics of immunoglobulin G following intravenous or subcutaneous administration of various immunoglobulin products in patients with primary immunodeficiencies. Int Immunopharmacol. 2022 Dec; 113(Pt A):109331. Li Z, Follman K, Freshwater E, Engler F, Yel L. PMID: 36461591.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    9. Pharmacokinetics and Biochemical Efficacy of an α1-Proteinase Inhibitor (Aralast NP) in α1-Antitrypsin Deficiency: a Cross-Product Retrospective Comparability Analysis. Pulm Ther. 2022 Sep; 8(3):311-326. Li Z, Franke RM, Morris DN, Yel L. PMID: 36001294; PMCID: PMC9458804.
      View in: PubMed   Mentions:
    10. Long-term safety of facilitated subcutaneous immunoglobulin treatment in pregnant women with primary immunodeficiency diseases: results from a registry study. Immunotherapy. 2022 06; 14(8):609-616. Borte M, Raffac S, Hrubiško M, Jahnz-Rozyk K, Garcia E, McCoy B, Chavan S, Nagy A, Yel L. PMID: 35443783.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    11. Comparative biochemical efficacy analysis of an alpha1-proteinase inhibitor (Glassia®) in patients with alpha-1 antitrypsin deficiency. Pulm Pharmacol Ther. 2022 06; 73-74:102124. Li Z, Franke RM, Morris D, Yel L. PMID: 35314325.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    12. Infection rates and tolerability of three different immunoglobulin administration modalities in patients with primary immunodeficiency diseases. Immunotherapy. 2022 03; 14(4):215-224. Wasserman RL, Gupta S, Stein M, Rabbat CJ, Engl W, Leibl H, Yel L. PMID: 34931880.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCTClinical Trials
    13. Population pharmacokinetic simulation of varied Immune Globulin Subcutaneous (Human), 20% solution (Ig20Gly) loading and maintenance dosing regimens in immunoglobulin-naïve patients with primary immunodeficiency diseases. Int Immunopharmacol. 2021 Nov; 100:108044. Li Z, Dumas T, Seth Berry N, McCoy B, Yel L. PMID: 34601202.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    14. Steady-State Serum IgG Trough Levels Are Adequate for Pharmacokinetic Assessment in Patients with Immunodeficiencies Receiving Subcutaneous Immune Globulin. J Clin Immunol. 2021 08; 41(6):1331-1338. Li Z, McCoy B, Engl W, Yel L. PMID: 34036490; PMCID: PMC8310849.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    15. Patient experience with subcutaneous immunoglobulin 20%, Ig20Gly, for primary immunodeficiency diseases: a prespecified post hoc analysis of combined data from 2 pivotal trials. BMC Immunol. 2020 05 04; 21(1):24. Meckley LM, Wu Y, Ito D, Berner T, McCoy B, Yel L. PMID: 32366233; PMCID: PMC7197164.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    16. Safety and tolerability of subcutaneous immunoglobulin 20% in primary immunodeficiency diseases from two continents. Immunotherapy. 2019 08; 11(12):1057-1065. Suez D, Kriván G, Jolles S, Stein M, Gupta S, Paris K, van Hagen PM, Brodszki N, Engl W, Leibl H, McCoy B, Yel L. PMID: 31268374.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCTClinical Trials
    17. Tolerability of Ig20Gly during onboarding in patients with primary immunodeficiency diseases. Ann Allergy Asthma Immunol. 2019 09; 123(3):271-279.e1. Gupta S, Stein M, Hussain I, Paris K, Engl W, McCoy B, Rabbat CJ, Yel L. PMID: 31228628.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCTClinical Trials
    18. Population pharmacokinetic modeling and simulation of immunoglobulin exposure with varying dosing intervals of subcutaneous immunoglobulin 20% (Ig20Gly) in patients with primary immunodeficiency diseases. Int Immunopharmacol. 2019 Jun; 71:404-410. Dumas T, Berry NS, Wolfsegger M, Jolles S, McCoy B, Yel L. PMID: 30952104.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    19. Tolerability of subcutaneous immunoglobulin 20%, Ig20Gly, in pediatric patients with primary immunodeficiencies. Immunotherapy. 2019 04; 11(5):397-406. Paris K, Haddad E, Borte M, Brodszki N, Dérfalvi B, Maródi L, Hussain I, Darter A, Engl W, Leibl H, McCoy B, Yel L. PMID: 30626238.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCTClinical Trials
    20. Response to the Letter to the Editor Regarding "Assessment of Local Adverse Reactions to Subcutaneous Immunoglobulin (SCIG) in Clinical Trials". J Clin Immunol. 2017 11; 37(8):739-740. Suez D, Stein M, Gupta S, Hussain I, Melamed I, Paris K, Darter A, Bourgeois C, Fritsch S, Leibl H, McCoy B, Gelmont D, Yel L. PMID: 28875256; PMCID: PMC5662656.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    21. Efficacy, safety, tolerability and pharmacokinetics of a novel human immune globulin subcutaneous, 20%: a Phase 2/3 study in Europe in patients with primary immunodeficiencies. Clin Exp Immunol. 2017 Jan; 187(1):146-159. Borte M, Kriván G, Derfalvi B, Maródi L, Harrer T, Jolles S, Bourgeois C, Engl W, Leibl H, McCoy B, Gelmont D, Yel L. PMID: 27613250; PMCID: PMC5167020.
      View in: PubMed   Mentions: 22     Fields:    Translation:HumansCTClinical Trials
    22. Efficacy, Safety, and Pharmacokinetics of a Novel Human Immune Globulin Subcutaneous, 20 % in Patients with Primary Immunodeficiency Diseases in North America. J Clin Immunol. 2016 10; 36(7):700-12. Suez D, Stein M, Gupta S, Hussain I, Melamed I, Paris K, Darter A, Bourgeois C, Fritsch S, Leibl H, McCoy B, Gelmont D, Yel L. PMID: 27582171; PMCID: PMC5018260.
      View in: PubMed   Mentions: 22     Fields:    Translation:HumansCTClinical Trials
    23. Recombinant human hyaluronidase facilitated subcutaneous immunoglobulin treatment in pediatric patients with primary immunodeficiencies: long-term efficacy, safety and tolerability. Immunotherapy. 2016 10; 8(10):1175-86. Wasserman RL, Melamed I, Kobrynski L, Puck J, Gupta S, Doralt J, Sharkhawy M, Engl W, Leibl H, Gelmont D, Yel L. PMID: 27468136.
      View in: PubMed   Mentions: 13     Fields:    Translation:HumansCTClinical Trials
    24. Long-Term Tolerability, Safety, and Efficacy of Recombinant Human Hyaluronidase-Facilitated Subcutaneous Infusion of Human Immunoglobulin for Primary Immunodeficiency. J Clin Immunol. 2016 08; 36(6):571-82. Wasserman RL, Melamed I, Stein MR, Engl W, Sharkhawy M, Leibl H, Puck J, Rubinstein A, Kobrynski L, Gupta S, Grant AJ, Ratnayake A, Richmond WG, Church J, Yel L, Gelmont D. PMID: 27220317; PMCID: PMC4940441.
      View in: PubMed   Mentions: 14     Fields:    Translation:HumansCTClinical Trials
    25. Common variable immunodeficiency associated with microdeletion of chromosome 1q42.1-q42.3 and inositol 1,4,5-trisphosphate kinase B (ITPKB) deficiency. Clin Transl Immunology. 2016 Jan; 5(1):e59. Louis AG, Yel L, Cao JN, Agrawal S, Gupta S. PMID: 26900472; PMCID: PMC4735063.
      View in: PubMed   Mentions: 8  
    26. A Novel Targeted Screening Tool for Hypogammaglobulinemia: Measurement of Serum Immunoglobulin (IgG, IgM, IgA) Levels from Dried Blood Spots (Ig-DBS Assay). J Clin Immunol. 2015 Aug; 35(6):573-82. Yel L, Rabbat CJ, Cunningham-Rundles C, Orange JS, Torgerson TR, Verbsky JW, Wang Y, Fu M, Robins TS, Edwards MS, Nymann-Andersen J. PMID: 26275445; PMCID: PMC4572045.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansPHPublic Health
    27. Autoimmunity and inflammation in X-linked agammaglobulinemia. J Clin Immunol. 2014 Aug; 34(6):627-32. Hernandez-Trujillo VP, Scalchunes C, Cunningham-Rundles C, Ochs HD, Bonilla FA, Paris K, Yel L, Sullivan KE. PMID: 24909997; PMCID: PMC4157090.
      View in: PubMed   Mentions: 36     Fields:    Translation:Humans
    28. Improving patient tolerability in immunoglobulin treatment: focus on stabilizer effects. Expert Rev Clin Immunol. 2013 Jun; 9(6):577-87. Sun A, Teschner W, Yel L. PMID: 23730887.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    29. T and B cell deficiency associated with yellow nail syndrome. Scand J Immunol. 2012 Mar; 75(3):329-35. Gupta S, Samra D, Yel L, Agrawal S. PMID: 21995335.
      View in: PubMed   Mentions: 11     Fields:    Translation:HumansCells
    30. H2AX gene does not have a modifier effect on ataxia-telangiectasia phenotype. Int J Immunogenet. 2011 Jun; 38(3):209-13. Mesci L, Ozdag H, Yel L, Ozgur TT, Tan C, Sanal O. PMID: 21199394.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCells
    31. Endonuclease G plays a role in immunoglobulin class switch DNA recombination by introducing double-strand breaks in switch regions. Mol Immunol. 2011 Jan; 48(4):610-22. Zan H, Zhang J, Al-Qahtani A, Pone EJ, White CA, Lee D, Yel L, Mai T, Casali P. PMID: 21111482; PMCID: PMC3412130.
      View in: PubMed   Mentions: 12     Fields:    Translation:HumansAnimalsCells
    32. Clinical features of chronic granulomatous disease: a series of 26 patients from a single center. Turk J Pediatr. 2010 Nov-Dec; 52(6):576-81. Turul-Ozgür T, Türkkani-Asal G, Tezcan I, Köker MY, Metin A, Yel L, Ersoy F, Sanal O. PMID: 21428188.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    33. Selective IgA deficiency. J Clin Immunol. 2010 Jan; 30(1):10-6. Yel L. PMID: 20101521; PMCID: PMC2821513.
      View in: PubMed   Mentions: 178     Fields:    Translation:HumansAnimals
    34. Clinical and immunological features in IgM deficiency. Int Arch Allergy Immunol. 2009; 150(3):291-8. Yel L, Ramanuja S, Gupta S. PMID: 19494527.
      View in: PubMed   Mentions: 31     Fields:    Translation:HumansCells
    35. Parvovirus B19-induced persistent pure red cell aplasia in a child with T-cell immunodeficiency. Pediatr Hematol Oncol. 2009 Mar; 26(2):63-8. Tavil B, Sanal O, Turul T, Yel L, Gurgey A, Gumruk F. PMID: 19322736.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCells
    36. Differential sensitivity of naïve and subsets of memory CD4+ and CD8+ T cells to hydrogen peroxide-induced apoptosis. Genes Immun. 2007 Oct; 8(7):560-9. Gupta S, Young T, Yel L, Su H, Gollapudi S. PMID: 17690685.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansCells
    37. A case of interleukin-12 receptor beta-1 deficiency with recurrent leishmaniasis. Pediatr Infect Dis J. 2007 Apr; 26(4):366-8. Sanal O, Turkkani G, Gumruk F, Yel L, Secmeer G, Tezcan I, Kara A, Ersoy F. PMID: 17414409.
      View in: PubMed   Mentions: 15     Fields:    Translation:Humans
    38. Arsenic trioxide induces apoptosis via the mitochondrial pathway by upregulating the expression of Bax and Bim in human B cells. Int J Oncol. 2007 Feb; 30(2):313-8. Baysan A, Yel L, Gollapudi S, Su H, Gupta S. PMID: 17203211.
      View in: PubMed   Mentions: 23     Fields:    Translation:HumansCells
    39. Health-related quality of life and treatment satisfaction in North American patients with primary immunedeficiency diseases receiving subcutaneous IgG self-infusions at home. J Clin Immunol. 2006 Jan; 26(1):65-72. Nicolay U, Kiessling P, Berger M, Gupta S, Yel L, Roifman CM, Gardulf A, Eichmann F, Haag S, Massion C, Ochs HD. PMID: 16418804.
      View in: PubMed   Mentions: 86     Fields:    Translation:Humans
    40. Thimerosal induces neuronal cell apoptosis by causing cytochrome c and apoptosis-inducing factor release from mitochondria. Int J Mol Med. 2005 Dec; 16(6):971-7. Yel L, Brown LE, Su K, Gollapudi S, Gupta S. PMID: 16273274.
      View in: PubMed   Mentions: 10     Fields:    Translation:AnimalsCells
    41. Role of NF-kappaB signaling pathway in increased tumor necrosis factor-alpha-induced apoptosis of lymphocytes in aged humans. Cell Death Differ. 2005 Feb; 12(2):177-83. Gupta S, Bi R, Kim C, Chiplunkar S, Yel L, Gollapudi S. PMID: 15647756.
      View in: PubMed   Mentions: 36     Fields:    Translation:HumansCells
    42. Molecular analysis of a large cohort of patients with the hyper immunoglobulin M (IgM) syndrome. Blood. 2005 Mar 01; 105(5):1881-90. Lee WI, Torgerson TR, Schumacher MJ, Yel L, Zhu Q, Ochs HD. PMID: 15358621.
      View in: PubMed   Mentions: 82     Fields:    Translation:Humans
    43. Defective anti-polysaccharide antibody response in patients with ataxia-telangiectasia. Turk J Pediatr. 2004 Jul-Sep; 46(3):208-13. Sanal O, Ozbas-Gerçeker F, Yel L, Ersoy F, Tezcan I, Berkel AI, Metin A, Gatti RA. PMID: 15503472.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCells
    44. Antibody response to a seven-valent pneumococcal conjugated vaccine in patients with ataxia-telangiectasia. J Clin Immunol. 2004 Jul; 24(4):411-7. Sanal O, Ersoy F, Tezcan I, Metin A, Turul T, Gariboglu S, Yel L. PMID: 15163897.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCellsCTClinical Trials
    45. Characterization of naïve, memory and effector CD8+ T cells: effect of age. Exp Gerontol. 2004 Apr; 39(4):545-50. Gupta S, Bi R, Su K, Yel L, Chiplunkar S, Gollapudi S. PMID: 15050289.
      View in: PubMed   Mentions: 41     Fields:    Translation:HumansCells
    46. Cellular immunodeficiency and autoimmunity in long-term mineral oil administration. Ann Allergy Asthma Immunol. 2004 Jan; 92(1):88-91. Yel L, Chen W, Gupta S. PMID: 14756470.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    47. A role of fas-associated death domain (FADD) in increased apoptosis in aged humans. J Clin Immunol. 2004 Jan; 24(1):24-9. Gupta S, Kim C, Yel L, Gollapudi S. PMID: 14997030.
      View in: PubMed   Mentions: 10     Fields:    Translation:HumansCells
    48. Severe T- and B-cell immune deficiency associated with malignant thymoma. Ann Allergy Asthma Immunol. 2003 Nov; 91(5):501-5. Yel L, Liao O, Lin F, Gupta S. PMID: 14692437.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCells
    49. Human uracil-DNA glycosylase deficiency associated with profoundly impaired immunoglobulin class-switch recombination. Nat Immunol. 2003 Oct; 4(10):1023-8. Imai K, Slupphaug G, Lee WI, Revy P, Nonoyama S, Catalan N, Yel L, Forveille M, Kavli B, Krokan HE, Ochs HD, Fischer A, Durandy A. PMID: 12958596.
      View in: PubMed   Mentions: 212     Fields:    Translation:HumansAnimalsCells
    50. Arsenic trioxide induces apoptosis in peripheral blood T lymphocyte subsets by inducing oxidative stress: a role of Bcl-2. Mol Cancer Ther. 2003 Aug; 2(8):711-9. Gupta S, Yel L, Kim D, Kim C, Chiplunkar S, Gollapudi S. PMID: 12939460.
      View in: PubMed   Mentions: 28     Fields:    Translation:HumansCells
    51. Effect of age on molecular signaling of TNF-alpha-induced apoptosis in human lymphocytes. Mech Ageing Dev. 2003 Apr; 124(4):503-9. Gupta S, Chiplunkar S, Kim C, Yel L, Gollapudi S. PMID: 12714259.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansCells
    52. Biochemical and molecular basis of thimerosal-induced apoptosis in T cells: a major role of mitochondrial pathway. Genes Immun. 2002 Aug; 3(5):270-8. Makani S, Gollapudi S, Yel L, Chiplunkar S, Gupta S. PMID: 12140745.
      View in: PubMed   Mentions: 19     Fields:    Translation:HumansCells
    53. Griscelli disease: genotype-phenotype correlation in an array of clinical heterogeneity. J Clin Immunol. 2002 Jul; 22(4):237-43. Sanal O, Ersoy F, Tezcan I, Metin A, Yel L, Ménasché G, Gürgey A, Berkel I, de Saint Basile G. PMID: 12148598.
      View in: PubMed   Mentions: 23     Fields:    Translation:HumansCells
    54. T-ALL with monoclonal gammopathy and hairy cell features. Am J Hematol. 2000 Oct; 65(2):166-70. Yetgin S, Olcay L, Yel L, Tuncer M, Tezcan I, Erdemli E, Oner AF, Behm FG. PMID: 10996836.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCells
    55. An allelic variant of Griscelli disease: presentation with severe hypotonia, mental-motor retardation, and hypopigmentation consistent with Elejalde syndrome (neuroectodermal melanolysosomal disorder). J Neurol. 2000 Jul; 247(7):570-2. Sanal O, Yel L, Kucukali T, Gilbert-Barnes E, Tardieu M, Texcan I, Ersoy F, Metin A, de Saint Basile G. PMID: 10993506.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansCells
    56. Isolated cutaneous response to granulocyte-monocyte colony stimulating factor in fatal idiopathic disseminated Bacillus-Calmette-Guerin infection. Eur J Pediatr. 2000 Mar; 159(3):149-52. Sanal O, Morgan G, Göçmen A, Novelli V, Klein N, Tezcan I, Ersoy F, Berkel AI, Yel L. PMID: 10664224.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCells
    57. Cartilage-hair hypoplasia syndrome: increased apoptosis of T lymphocytes is associated with altered expression of Fas (CD95), FasL (CD95L), IAP, Bax, and Bcl2. J Clin Immunol. 1999 Nov; 19(6):428-34. Yel L, Aggarwal S, Gupta S. PMID: 10634217.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCells
    58. Bronchiectasis due to ciliary aplasia in Turner's syndrome. Turk J Pediatr. 1999 Oct-Dec; 41(4):525-9. Ozçelik U, Tuncel M, Göçmen A, Balci S, Erbil M, Yel L, Kiper N. PMID: 10770124.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCells
    59. Impaired IgG antibody production to pneumococcal polysaccharides in patients with ataxia-telangiectasia. J Clin Immunol. 1999 Sep; 19(5):326-34. Sanal O, Ersoy F, Yel L, Tezcan I, Metin A, Ozyürek H, Gariboglu S, Fikrig S, Berkel AI, Rijkers GT, Zegers BJ. PMID: 10535610.
      View in: PubMed   Mentions: 15     Fields:    Translation:HumansCells
    60. A case of chronic severe neutropenia: oral findings and consequences of short-term granulocyte colony-stimulating factor treatment. Aust Dent J. 1998 Feb; 43(1):9-13. Hastürk H, Tezcan I, Yel L, Ersoy F, Sanal O, Yamalik N, Berker E. PMID: 9583218.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansCells
    61. Defective serum opsonization activity in children aged 6-48 months having acute purulent otitis media. Turk J Pediatr. 1997 Oct-Dec; 39(4):453-7. Tezcan I, Yilmaz Y, Oner F, Yel L, Sanal O, Ersoy F, Onerci M, Berkel AI. PMID: 9433146.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansAnimals
    62. Mutations in the mu heavy-chain gene in patients with agammaglobulinemia. N Engl J Med. 1996 Nov 14; 335(20):1486-93. Yel L, Minegishi Y, Coustan-Smith E, Buckley RH, Trübel H, Pachman LM, Kitchingman GR, Campana D, Rohrer J, Conley ME. PMID: 8890099.
      View in: PubMed   Mentions: 52     Fields:    Translation:HumansCells
    63. Dyskeratosis congenita: unusual onset with isolated neutropenia at an early age. Acta Paediatr Jpn. 1996 Jun; 38(3):288-90. Yel L, Tezcan I, Sanal O, Ersoy F, Berkel AI. PMID: 8741326.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCells
    64. Homozygous C2 deficiency: association with defective alternative pathway function and immunoglobulin deficiency. Int Arch Allergy Immunol. 1996 Jun; 110(2):195-8. Sanal O, Yel L, Tezcan I, Ersoy F, Berkel AI. PMID: 8645999.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    65. Low expression of T-cell receptor-CD3 complex: a case with a clinical presentation resembling humoral immunodeficiency. Turk J Pediatr. 1996 Jan-Mar; 38(1):81-4. Sanal O, Yel L, Ersoy F, Tezcan I, Berkel AI. PMID: 8819625.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    66. Selective IgA deficiency with unusual features: development of common variable immunodeficiency, Sjögren's syndrome, autoimmune hemolytic anemia and immune thrombocytopenic purpura. Acta Paediatr Jpn. 1995 Aug; 37(4):526-9. Sanal O, Ersoy F, Metin A, Tezcan I, Berkel AI, Yel L. PMID: 7572159.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    67. Bare lymphocyte syndrome with lack of HLA class I and II antigens. Presentation of two cases. Turk J Pediatr. 1995 Apr-Jun; 37(2):141-6. Ersoy F, Sanal O, Tezcan I, Yel L, Metin A. PMID: 7597764.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    68. Oral findings, treatment and follow-up of a case with major aphthous stomatitis (Sutton's disease). J Clin Pediatr Dent. 1994; 19(1):49-53. Yel L, Tezcan I, Hasturk H, Ersoy F, Sanal O, Yavuzyilmaz E. PMID: 7865424.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    69. [Convulsions in childhood Shigella gastroenteritis. An evaluation of risk factors]. Mikrobiyol Bul. 1990 Oct; 24(4):352-6. Seçmeer G, Kanra G, Ceyhan M, Anlar FY, Yel L. PMID: 2287293.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    With one click, see people who:

    Run Clinical Trials

    See more options in the Advanced Search tab

    Leman's Networks
    Concepts (353)
    Derived automatically from this person's publications.
    Explore
    _
    Co-Authors (4)
    People in Profiles who have published with this person.
    Explore
    _
    Similar People (60)
    People who share similar concepts with this person.
    Explore
    _
    Same Department
    Search Department
    _

    UCI Profiles is managed by the UCSF Clinical and Translational Science Institute (CTSI), part of the Clinical and Translational Science Award program funded by the National Center for Advancing Translational Sciences (Grant Number UL1 TR000004) at the National Institutes of Health (NIH).
    This site is running Profiles RNS version UCSF-v3.1.0-3-g1ef1264b on PROFILES-PWEB03. We use cookies to operate our website. We also use cookies to analyze our site’s performance and improve your experience on our site. For more information about how we use cookies, please see our Website Terms of Use.

    Copyright © The Regents of the University of California